Activated protein C for sepsis

New England Journal of Medicine

Volumn 362, Issue 12, 2010, Pages 1150-1151

  Mackenzie, Alasdair ^a  

^a QUEEN MARGARET HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DROTRECOGIN; PLACEBO;

EMERGENCY SURGERY; FOOD AND DRUG ADMINISTRATION; HUMAN; LETTER; MORTALITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; SEPSIS; TREATMENT OUTCOME;

EID: 77950197710     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1000961     Document Type: Letter

References (6)

1. Toussaint S, Gerlach H. Activated protein C for sepsis. N Engl J Med 2009;361:2646-2652
2. Bernard GR, Vincent JL, Laterre P-F, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709.
3. FDA clinical review - drotrecogin alfa (activated) (uneven randomisation: Table 19). November 2001. (Accessed March 4, 2010, at http://www.fda.gov/ downloads/Drugs/Development ApprovalProcess/HowDrugsareDevelopedandApproved/ Approval Applications/TherapeuticBiologicApplications/ UCM113438.pdf.)
4. Surgical data (Table 97). (Accessed March 4, 2010, at http:// www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/ HowDrugsareDevelopedandApproved/ApprovalApplications/ TherapeuticBiologicApplications/UCM113441.pdf.)
5. Barie PS, Williams MD, McCollam JS, et al. Benefit/risk pro file of drotrecogin alfa (activated) in surgical patients with severe sepsis. Am J Surg 2004;188:212-220
6. Abraham E, Laterre P-F, Garg R, et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005;353:1332-1341